AR122743A2 - Composición farmacéutica de antagonistas de unión al eje pd-1 e inhibidores de mek - Google Patents

Composición farmacéutica de antagonistas de unión al eje pd-1 e inhibidores de mek

Info

Publication number
AR122743A2
AR122743A2 ARP210101755A ARP210101755A AR122743A2 AR 122743 A2 AR122743 A2 AR 122743A2 AR P210101755 A ARP210101755 A AR P210101755A AR P210101755 A ARP210101755 A AR P210101755A AR 122743 A2 AR122743 A2 AR 122743A2
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
axis
mek inhibitors
binding antagonist
binding antagonists
Prior art date
Application number
ARP210101755A
Other languages
English (en)
Inventor
Heather Maecker
Bryan Irving
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR122743A2 publication Critical patent/AR122743A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención describe una composición farmacéutica para tratamiento combinado que comprende un antagonistas de unión al eje PD-1 y un inhibidor de MEK y el uso de los mismos en la manufactura de dicha composición, que se aplica en para tratar afecciones donde se desea inmunogenicidad potenciada tal como el aumento de la inmunogenicidad tumoral para el tratamiento del cáncer. Reivindicación 1: Una composición farmacéutica caracterizada porque comprende una cantidad efectiva de un antagonista de unión al eje PD-1 en un primer medicamento y un inhibidor de MEK en un segundo medicamento, donde el antagonista de unión al eje PD-1 es un anticuerpo anti-PD-L1, y donde el inhibidor de MEK se selecciona del grupo que consiste de los compuestos del grupo de fórmulas (1), o una sal o solvato aceptable para uso farmacéutico del mismo.
ARP210101755A 2011-08-01 2021-06-25 Composición farmacéutica de antagonistas de unión al eje pd-1 e inhibidores de mek AR122743A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161574406P 2011-08-01 2011-08-01

Publications (1)

Publication Number Publication Date
AR122743A2 true AR122743A2 (es) 2022-10-05

Family

ID=46717934

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP120102796A AR087405A1 (es) 2011-08-01 2012-08-01 Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
ARP210101755A AR122743A2 (es) 2011-08-01 2021-06-25 Composición farmacéutica de antagonistas de unión al eje pd-1 e inhibidores de mek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP120102796A AR087405A1 (es) 2011-08-01 2012-08-01 Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek

Country Status (27)

Country Link
US (2) US9724413B2 (es)
EP (1) EP2739358B1 (es)
JP (3) JP6238459B2 (es)
KR (2) KR102049817B1 (es)
CN (1) CN103842030B (es)
AR (2) AR087405A1 (es)
AU (4) AU2012290121B2 (es)
BR (2) BR122022000334B1 (es)
CA (1) CA2843595C (es)
CO (1) CO6900118A2 (es)
CR (1) CR20140034A (es)
EA (1) EA026924B1 (es)
EC (1) ECSP14013223A (es)
ES (1) ES2708669T3 (es)
IL (2) IL230647B (es)
MA (1) MA35366B1 (es)
MX (2) MX368257B (es)
MY (2) MY193562A (es)
PE (2) PE20190262A1 (es)
PH (1) PH12018500365B1 (es)
PL (1) PL2739358T3 (es)
SG (1) SG10201606284UA (es)
TR (1) TR201820873T4 (es)
TW (4) TWI835048B (es)
UA (1) UA117220C2 (es)
WO (1) WO2013019906A1 (es)
ZA (1) ZA201400612B (es)

Families Citing this family (351)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE493433T1 (de) 2002-09-11 2011-01-15 Genentech Inc Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
EP3208612B1 (en) 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2288379A4 (en) 2008-05-19 2012-08-08 Advaxis DOUBLE RELEASE SYSTEM FOR HETEROLOGIST ANTIGENE
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP3929216A1 (en) 2008-12-09 2021-12-29 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
SI2694075T1 (sl) 2011-04-01 2016-07-29 Curis, Inc. Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
PE20190262A1 (es) 2011-08-01 2019-02-25 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
CA2862390A1 (en) 2012-01-25 2013-08-01 Dnatrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
CN103566377A (zh) * 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
KR20150127203A (ko) * 2013-03-14 2015-11-16 제넨테크, 인크. Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
ES2761260T3 (es) * 2013-03-15 2020-05-19 Hoffmann La Roche Biomarcadores y procedimientos de tratamiento de afecciones relacionadas con PD-1 y PD-L1
JP6361039B2 (ja) * 2013-04-03 2018-07-25 アイビーシー ファーマスーティカルズ，インコーポレイテッド 疾患に対する免疫反応を誘導するための併用療法
US10010608B2 (en) * 2013-05-31 2018-07-03 Merck Sharp & Dohme Corp. Combination therapies for cancer
JP2016520643A (ja) 2013-06-03 2016-07-14 ノバルティス アーゲー 抗ｐｄ−ｌ１抗体とｍｅｋ阻害薬および／またはｂｒａｆ阻害薬の組み合わせ物
WO2014204856A1 (en) * 2013-06-17 2014-12-24 Catabasis Pharmaceuticals, Inc. Fatty acid anticancer derivatives and their uses
BR112016000853A2 (pt) 2013-07-16 2017-12-12 Genentech Inc métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
ES2827679T3 (es) 2013-08-20 2021-05-24 Merck Sharp & Dohme Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
CN112457403B (zh) 2013-09-13 2022-11-29 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
AU2014324703C1 (en) * 2013-09-27 2020-10-29 Genentech, Inc. Anti-PDL1 antibody formulations
EP3052131B1 (en) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
US10241115B2 (en) 2013-12-10 2019-03-26 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
CA2934028A1 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
JP2017501157A (ja) * 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法
KR20240017102A (ko) * 2013-12-17 2024-02-06 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
US20160304969A1 (en) 2013-12-17 2016-10-20 Merck Sharp & Dohme Corp. Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
CN114671954A (zh) 2014-01-10 2022-06-28 博笛生物科技有限公司 靶向her2阳性肿瘤的化合物和组合物
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015119944A1 (en) 2014-02-04 2015-08-13 Incyte Corporation Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
MX2016010082A (es) 2014-02-04 2016-10-07 Pfizer Combinacion de un antagonista de proteina de muerte programada 1 (pd-1) y un inhibidor del receptor del factor de crecimiento endotelial vascular (vegfr) para tratar cancer.
US10899840B2 (en) 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
RS62038B1 (sr) * 2014-02-10 2021-07-30 Merck Patent Gmbh Ciljana tgf beta inhibicija
HUE048531T2 (hu) 2014-03-14 2020-07-28 Novartis Ag Antitest molekulák a LAG-3-hoz és ezek felhasználása
US11230719B2 (en) 2014-03-26 2022-01-25 Denovo Biopharma Llc Retroviral vector having immune-stimulating activity
JP6588461B2 (ja) 2014-03-31 2019-10-09 ジェネンテック， インコーポレイテッド 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
WO2015179654A1 (en) * 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
KR20170005492A (ko) 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
EP3998079A1 (en) 2014-06-06 2022-05-18 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
CN105440135A (zh) * 2014-09-01 2016-03-30 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN107074958A (zh) 2014-07-09 2017-08-18 博笛生物科技有限公司 用于治疗肿瘤的抗‑pd‑l1组合
DK3309174T3 (da) 2014-07-11 2022-06-07 Ventana Med Syst Inc ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
SG10202007111TA (en) * 2014-07-15 2020-09-29 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
US9907849B2 (en) 2014-07-18 2018-03-06 Advaxis, Inc. Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer
SG11201700496WA (en) 2014-07-22 2017-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
WO2016014148A1 (en) 2014-07-23 2016-01-28 Mayo Foundation For Medical Education And Research Targeting dna-pkcs and b7-h1 to treat cancer
EP3177644B1 (en) 2014-08-05 2020-10-07 Mabquest SA Immunological reagents binding to pd-1
CN110964108B (zh) 2014-08-05 2023-07-07 中美冠科生物技术（太仓）有限公司 抗pd-l1抗体
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
US9546206B2 (en) 2014-08-08 2017-01-17 The Board Of Trustees Of The Leland Stanford Junior University High affinity PD-1 agents and methods of use
KR102443258B1 (ko) 2014-08-12 2022-09-14 엘리게이터 바이오사이언스 에이비 항 cd40 항체에 의한 병용 치료제
CN106659780A (zh) * 2014-08-14 2017-05-10 豪夫迈·罗氏有限公司 活化人cd40的抗体和针对人pd‑l1的抗体的组合疗法
EP3070102A1 (en) * 2015-03-18 2016-09-21 F. Hoffmann-La Roche AG Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
EP3825305A1 (en) 2014-08-28 2021-05-26 Eisai R&D Management Co., Ltd. Process for preparing lenvatinib
PT3186281T (pt) 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
US9535074B2 (en) 2014-09-08 2017-01-03 Merck Sharp & Dohme Corp. Immunoassay for soluble PD-L1
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
CN106687135A (zh) * 2014-09-15 2017-05-17 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和il‑17结合拮抗剂治疗癌症的方法
SI3193931T1 (sl) 2014-09-16 2020-12-31 Innate Pharma Nevtralizacija inhibitornih poti v limfocitih
ES2774448T3 (es) 2014-10-03 2020-07-21 Novartis Ag Terapias de combinación
IL251669B2 (en) 2014-10-10 2023-02-01 Idera Pharmaceuticals Inc Cancer treatment using a tlr9 agonist with checkpoint inhibitors
PT3204417T (pt) 2014-10-10 2020-10-08 Innate Pharma Bloqueio de cd73
TN2017000129A1 (en) 2014-10-14 2018-10-19 Dana Farber Cancer Inst Inc Antibody molecules to pd-l1 and uses thereof
CA3126536C (en) 2014-10-14 2023-07-25 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2016081384A1 (en) * 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
ES2835823T3 (es) * 2014-11-20 2021-06-23 Hoffmann La Roche Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1
CN105669862A (zh) * 2014-11-21 2016-06-15 上海中信国健药业股份有限公司 抗人pd-l1/kir双特异性抗体及其制备方法和应用
MX2017007321A (es) * 2014-12-02 2017-08-25 Celgene Corp Terapias de combinacion.
EP3226689B1 (en) 2014-12-05 2020-01-15 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
US10086000B2 (en) 2014-12-05 2018-10-02 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
WO2016089797A1 (en) 2014-12-05 2016-06-09 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
US20160158360A1 (en) * 2014-12-05 2016-06-09 Genentech, Inc. Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
AU2015360736A1 (en) 2014-12-09 2017-06-01 Merck Sharp & Dohme Corp. System and methods for deriving gene signature biomarkers of response to PD-1 antagonists
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
WO2016106160A1 (en) * 2014-12-22 2016-06-30 Enumeral Biomedical Holdings, Inc. Methods for screening therapeutic compounds
EP3240908A2 (en) * 2014-12-30 2017-11-08 F. Hoffmann-La Roche AG Methods and compositions for prognosis and treatment of cancers
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
PT3263106T (pt) 2015-02-25 2024-01-12 Eisai R&D Man Co Ltd Método para suprimir o amargor do derivado de quinolina
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
EP3265122B1 (en) 2015-03-04 2022-05-04 Merck Sharp & Dohme Corp. Combination of pembrolizumab and eribulin for treating triple-negative breast cancer
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
ES2844799T3 (es) 2015-04-17 2021-07-22 Merck Sharp & Dohme Biomarcadores sanguíneos de sensibilidad tumoral a antagonistas de PD-1
DK3285809T3 (da) * 2015-04-20 2019-11-18 Effector Therapeutics Inc Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
WO2016179576A1 (en) * 2015-05-07 2016-11-10 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer
WO2016191397A1 (en) * 2015-05-22 2016-12-01 Td2 Inc. Benzamide and active compound compositions and methods of use
EP3303361A1 (en) 2015-05-27 2018-04-11 Idenix Pharmaceuticals LLC Nucleotides for the treatment of cancer
KR20180014009A (ko) * 2015-05-29 2018-02-07 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합
CA2984638A1 (en) * 2015-05-29 2016-12-08 Genentech, Inc. Pd-l1 promoter methylation in cancer
KR102647100B1 (ko) 2015-05-30 2024-03-13 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드 및 이를 포함하는 세포-표적화 분자
CA2985818A1 (en) * 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions comprising an antagonist of porcupine and a pd-l/pd-1 axis antagonist for immunotherapy
IL256245B (en) 2015-06-16 2022-09-01 Merck Patent Gmbh Treatments that combine a pd-l1 antagonist
KR20180018695A (ko) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 항암제
WO2016205200A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cll-1 antibodies and methods of use
JP6896650B2 (ja) * 2015-06-17 2021-06-30 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
EP3779998A1 (en) * 2015-07-13 2021-02-17 Biodesix, Inc. Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods
MA42459A (fr) 2015-07-16 2018-05-23 Bioxcel Therapeutics Inc Nouvelle approche pour le traitement du cancer par immunomodulation
CN116196426A (zh) 2015-07-16 2023-06-02 百欧肯治疗有限公司 治疗癌症的组合物及方法
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
JP6878405B2 (ja) 2015-07-29 2021-05-26 ノバルティス アーゲー Ｐｄ−１に対する抗体分子を含む組み合わせ治療
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3334745B1 (en) 2015-08-13 2024-05-15 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
US20170114098A1 (en) 2015-09-03 2017-04-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
BR112018005862A2 (pt) 2015-09-25 2018-10-16 Genentech, Inc. anticorpos, anticorpos isolados, polinucleotídeo, vetor, célula hospedeira, método de produção do anticorpo, imunoconjugado, composição, usos dos anticorpos, métodos para tratar ou retardar a progressão de um câncer e de uma doença e para aumentar, potencializar ou estimular uma resposta ou função imune e kit
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
PE20240096A1 (es) 2015-10-02 2024-01-18 Hoffmann La Roche Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
CN108136010A (zh) * 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法
EP3362475B1 (en) 2015-10-12 2023-08-30 Innate Pharma Cd73 blocking agents
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
WO2017079112A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
AU2016362697B2 (en) 2015-12-03 2018-07-12 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of STING
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
US10538497B2 (en) 2015-12-15 2020-01-21 Merck Sharp & Dohme Corp. Compounds as indoleamine 2,3-dioxygenase inhibitors
GB201522309D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use
GB201522311D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CA3006529A1 (en) * 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
EP3868787A1 (en) 2016-01-21 2021-08-25 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
CA3012075A1 (en) 2016-01-22 2017-07-27 MabQuest SA Immunological reagents
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
WO2017136139A1 (en) 2016-02-01 2017-08-10 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy
AU2017230850B2 (en) 2016-03-08 2024-04-18 Innate Pharma Siglec neutralizing antibodies
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
JP7137474B2 (ja) 2016-03-15 2022-09-14 メルサナ セラピューティクス，インコーポレイティド ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
AU2017235097B2 (en) * 2016-03-15 2023-08-31 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
JP7069032B2 (ja) 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
EP3436829A1 (en) 2016-03-30 2019-02-06 Centre Léon-Bérard Lymphocytes expressing cd73 in cancerous patient dictates therapy
CN109071514B (zh) 2016-04-07 2021-07-06 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
BR112018070602A2 (pt) 2016-04-07 2019-02-05 Glaxosmithkline Ip Dev Ltd composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
JP6911048B2 (ja) 2016-04-12 2021-07-28 イーライ リリー アンド カンパニー がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
EP3443120A2 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Methods for monitoring and treating cancer
JP2019515035A (ja) * 2016-04-27 2019-06-06 ミラ ディーエックス， インコーポレイテッド Ｋｒａｓバリアントがん患者の免疫ベースの処置
WO2017192874A1 (en) 2016-05-04 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Albumin-binding immunomodulatory compositions and methods of use thereof
WO2017191545A1 (en) 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
TWI755395B (zh) 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
CN109475629A (zh) 2016-05-20 2019-03-15 伊莱利利公司 用notch和pd-1或pd-l1抑制剂的组合治疗
CA3026983A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
EP3468960B1 (en) 2016-06-08 2022-03-23 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
AU2017300123A1 (en) 2016-07-20 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as PERK inhibitors
WO2018029124A1 (en) * 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
MX2019003603A (es) * 2016-09-29 2019-08-01 Genentech Inc Terapia de combinacion con un inhibidor de mek, un inhibidor del eje pd-1 y un taxano.
BR112019006816A8 (pt) 2016-10-04 2023-02-07 Merck Sharp & Dohme Compostos de benzo[b]tiofeno como agonistas de sting, composição farmacêutica e uso dos mesmos
WO2018065938A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
SG11201902974PA (en) 2016-10-14 2019-05-30 Merck Sharp & Dohme Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
AU2017353427A1 (en) 2016-11-02 2019-05-16 Bristol-Myers Squibb Company Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
EP3538137A2 (en) 2016-11-08 2019-09-18 Qilu Puget Sound Biotherapeutics Corporation Anti-pd1 and anti-ctla4 antibodies
EP3541825A1 (en) 2016-11-21 2019-09-25 Idenix Pharmaceuticals LLC. Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
WO2018100534A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
CA3045243A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
EP3551663A1 (en) * 2016-12-12 2019-10-16 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
WO2018115051A1 (en) 2016-12-22 2018-06-28 F. Hoffmann-La Roche Ag Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
CN108239149B (zh) * 2016-12-25 2021-03-05 南京传奇生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体
WO2018127570A1 (en) 2017-01-05 2018-07-12 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
WO2018129301A1 (en) 2017-01-05 2018-07-12 Biodesix, Inc. Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups
TWI774726B (zh) 2017-01-25 2022-08-21 英屬開曼群島商百濟神州有限公司 (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途
CN110234403A (zh) 2017-01-27 2019-09-13 詹森生物科技公司 作为sting激动剂的环状二核苷酸
CN110234404A (zh) 2017-01-27 2019-09-13 詹森生物科技公司 作为sting激动剂的环状二核苷酸
EP3577138A1 (en) 2017-02-06 2019-12-11 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
KR102628557B1 (ko) 2017-02-21 2024-01-29 리제너론 파아마슈티컬스, 인크. 폐암의 치료를 위한 항-pd-1 항체
CN108503691B (zh) * 2017-02-25 2021-07-23 复旦大学 一种人pd-l1蛋白高亲和性肽及其应用
BR112019017738A2 (pt) 2017-02-27 2020-04-07 Glaxosmithkline Ip Dev Ltd combinação, composição farmacêutica, uso de uma combinação ou composição farmacêutica, método para tratar câncer em um humano, e, composto
WO2018160538A1 (en) 2017-02-28 2018-09-07 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
EP3596469A1 (en) 2017-03-12 2020-01-22 Yeda Research and Development Co., Ltd. Methods of diagnosing and prognosing cancer
CN110382544B (zh) 2017-03-16 2023-12-22 先天制药公司 用于治疗癌症的组合物和方法
CA3058276A1 (en) 2017-03-30 2018-10-04 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
EP3628070B1 (en) 2017-04-28 2021-09-08 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides for use in increasing central memory t cells
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
KR20200006115A (ko) 2017-05-16 2020-01-17 브리스톨-마이어스 스큅 컴퍼니 항-gitr 효능제 항체에 의한 암의 치료
WO2018222949A1 (en) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2018226336A1 (en) 2017-06-09 2018-12-13 Providence Health & Services - Oregon Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer
BR112019025325A2 (pt) 2017-06-09 2020-06-23 Glaxosmithkline Intellectual Property Development Limited Métodos para tratar câncer, para fabricar um anticorpo anti-icos ou porção de ligação a antígeno do mesmo, para fabricar um anticorpo anti-pd1 ou porção de ligação a antígeno do mesmo, para fabricar um anticorpo anti-pdl1 ou porção de ligação a antígeno do mesmo, anticorpo anti-icos ou fragmento de ligação a antígeno do mesmo e um anticorpo anti-pd1 ou fragmento de ligação a antígeno do mesmo, anticorpo anti-icos ou fragmento de ligação a antígeno do mesmo e um anticorpo anti-pd-l1 ou fragmento de ligação a antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação a antígeno do mesmo e um anticorpo anti-pd1 ou porção de ligação a antígeno do mesmo, polinucleotídeo, vetor, e, célula hospedeira
EP3641771A4 (en) 2017-06-23 2020-12-16 Birdie Biopharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS
KR20200020902A (ko) 2017-06-26 2020-02-26 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
WO2019008506A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
BR112020000086A2 (pt) 2017-07-03 2020-07-07 Glaxosmithkline Intellectual Property Development Limited derivados de 2-(4-clorofenóxi)-n-((1-(2-(4-clorofenóxi) etinazetidin-3-il) metil) acetamida e compostos relacionados como inibidores de atf4 para tratamento de câncer e outras doenças
CA3066514A1 (en) 2017-07-10 2019-01-17 Innate Pharma Siglec-9-neutralizing antibodies
US11293066B2 (en) 2017-07-18 2022-04-05 Institut Gustave Roussy Method for assessing the response to PD-1/PDL-1 targeting drugs
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
TW201922721A (zh) 2017-09-07 2019-06-16 英商葛蘭素史克智慧財產發展有限公司 化學化合物
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
TW201927771A (zh) 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
BR112020006780A2 (pt) 2017-10-05 2020-10-06 Glaxosmithkline Intellectual Property Development Limited moduladores do estimulador de genes do interferon (sting)
KR20200060471A (ko) 2017-10-06 2020-05-29 이나뜨 파르마 Cd39/cd73 축을 통한 t 세포 활성의 복원
CN109663130B (zh) * 2017-10-13 2021-06-29 江苏恒瑞医药股份有限公司 Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
BR112020007046A2 (pt) 2017-10-19 2020-11-17 Debiopharm International S.A. produto de combinação para o tratamento do câncer
WO2019089412A1 (en) 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CA3082108A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
WO2019099294A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CA3081602A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
CN108165536A (zh) * 2017-12-11 2018-06-15 浙江大学 一种重组溶瘤痘苗病毒及其制备方法与应用
MX2020006290A (es) 2017-12-15 2020-12-03 Janssen Biotech Inc Dinucleotidos ciclicos como agonistas de sting.
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
AU2018396970A1 (en) 2017-12-28 2020-08-13 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against TIGIT
MX2020007404A (es) * 2018-01-10 2020-09-14 Array Biopharma Inc Metodos y terapia de combincion para tratar cancer.
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
US20210069246A1 (en) 2018-01-31 2021-03-11 Celgene Corporation Combination therapy using adoptive cell therapy and checkpoint inhibitor
CN111867589A (zh) 2018-03-14 2020-10-30 默克专利股份有限公司 在对象中治疗肿瘤的化合物及其用途
MA52189A (fr) 2018-04-03 2021-02-17 Merck Sharp & Dohme Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
US11542505B1 (en) 2018-04-20 2023-01-03 Merck Sharp & Dohme Llc Substituted RIG-I agonists: compositions and methods thereof
CN112352052A (zh) 2018-05-04 2021-02-09 托利斯有限公司 激活上皮细胞和髓样细胞的tlr3配体
CA3099079A1 (en) 2018-05-04 2019-11-07 Merck Patent Gmbh Combined inhibition of pd-1/pd-l1, tgf.beta. and dna-pk for the treatment of cancer
EP3790584A4 (en) * 2018-05-07 2022-03-30 Genmab A/S METHOD OF TREATMENT OF CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DUG CONJUGATE
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
JOP20200303A1 (ar) 2018-05-24 2020-11-23 Janssen Biotech Inc عوامل ربط psma واستخداماتها
EP3810116B1 (en) 2018-05-31 2023-11-15 Merck Sharp & Dohme LLC Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
US20210253614A1 (en) 2018-05-31 2021-08-19 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
WO2019234576A1 (en) 2018-06-03 2019-12-12 Lamkap Bio Beta Ltd. Bispecific antibodies against ceacam5 and cd47
WO2019242505A1 (zh) 2018-06-17 2019-12-26 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
BR112020024412A8 (pt) 2018-06-18 2023-03-21 Innate Pharma Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação
CN111902428B (zh) 2018-07-03 2023-11-10 上海健信生物医药科技有限公司 一种双特异性抗体及其用途
US20210253528A1 (en) 2018-07-09 2021-08-19 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN118147029A (zh) 2018-07-11 2024-06-07 阿克蒂姆治疗有限公司 工程化的免疫刺激性细菌菌株及其用途
EP3827020A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
BR112021004371A2 (pt) 2018-09-11 2021-05-25 Curis Inc. terapia em combinação com um inibidor de fosfoinositídeo 3-quinase com uma porção de ligação a zinco
US20220048997A1 (en) 2018-09-26 2022-02-17 Merck Patent Gmbh Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
MX2021004291A (es) 2018-10-17 2021-08-16 Biolinerx Ltd Tratamiento del adenocarcinoma pancreatico metastasico.
CA3117746A1 (en) 2018-10-22 2020-04-30 Glaxosmithkline Intellectual Property Development Limited Dosing
US20230021500A1 (en) 2018-10-29 2023-01-26 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
EP3873464A4 (en) 2018-11-01 2022-06-08 Merck Sharp & Dohme Corp. NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS
EP3877366A4 (en) 2018-11-06 2022-08-24 Merck Sharp & Dohme Corp. NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS
US20220010017A1 (en) * 2018-11-14 2022-01-13 Bayer Aktiengesellschaft Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
CA3119742A1 (en) 2018-11-16 2020-05-22 Arqule, Inc. Pharmaceutical combination for treatment of cancer
KR20210093964A (ko) 2018-11-20 2021-07-28 머크 샤프 앤드 돔 코포레이션 치환된 아미노 트리아졸로피리미딘 및 아미노 트리아졸로피라진 아데노신 수용체 길항제, 제약 조성물 및 그의 용도
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
CN113453678A (zh) 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
US20230008022A1 (en) 2018-11-28 2023-01-12 Merck Sharp & Dohme Corp. Novel substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
IL283487B1 (en) 2018-11-30 2024-03-01 Glaxosmithkline Ip Dev Ltd Compounds useful in curing HIV
MX2021006329A (es) 2018-11-30 2021-08-11 Merck Sharp & Dohme Llc Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso.
US10952996B2 (en) 2018-12-11 2021-03-23 Theravance Biopharma R&D Ip, Llc ALK5 inhibitors
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
EP3924054A1 (en) 2019-02-15 2021-12-22 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN109879855B (zh) * 2019-03-26 2021-01-05 中国医学科学院医药生物技术研究所 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用
US20220177465A1 (en) 2019-04-04 2022-06-09 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
MA55717A (fr) 2019-04-19 2022-02-23 Janssen Biotech Inc Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
KR20220002959A (ko) 2019-04-23 2022-01-07 이나뜨 파르마 에스.에이. Cd73 차단 항체
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
US20220251079A1 (en) 2019-05-16 2022-08-11 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
CA3141531A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
WO2020260547A1 (en) 2019-06-27 2020-12-30 Rigontec Gmbh Design method for optimized rig-i ligands
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021012092A1 (en) * 2019-07-19 2021-01-28 Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. A novel anti-pd-l1 antibody and use thereof
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2021026009A1 (en) 2019-08-02 2021-02-11 Mersana Therapeutics, Inc. Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
RS65480B1 (sr) 2019-09-18 2024-05-31 Lamkap Bio Alpha AG Bispecifična antitela protiv ceacam5 i cd3
EP4031573A1 (en) 2019-09-20 2022-07-27 Transgene Combination of a poxvirus encoding hpv polypeptides and il-2 with an anti-pd-l1 antibody
TW202128755A (zh) 2019-09-27 2021-08-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 抗原結合蛋白
WO2021083060A1 (zh) 2019-10-28 2021-05-06 中国科学院上海药物研究所 五元杂环氧代羧酸类化合物及其医药用途
MX2022005056A (es) 2019-10-29 2022-05-18 Eisai R&D Man Co Ltd Combinacion de un antagonista de pd-1, un inhibidor tirosina cinasa de vegfr/fgfr/ret y un inhibidor de cbp/beta-catenina para el tratamiento del cancer.
EP4061809A1 (en) 2019-11-22 2022-09-28 Theravance Biopharma R&D IP, LLC Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
EP4069683A1 (en) 2019-12-06 2022-10-12 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
US11673879B2 (en) 2020-03-31 2023-06-13 Theravance Biopharma R&D Ip, Llc Substituted pyrimidines and methods of use
AU2021256925A1 (en) 2020-04-14 2022-11-03 Ares Trading S.A. Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
TW202206100A (zh) 2020-04-27 2022-02-16 美商西健公司 癌症之治療
BR112022022452B1 (pt) 2020-05-06 2023-11-21 Merck Sharp & Dohme Llc Compostos inibidores de il4i1, usos dos mesmos e composições farmacêuticas que os compreendem
WO2021249969A1 (en) 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
JP2023530275A (ja) 2020-06-10 2023-07-14 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ａｌｋ５阻害剤として有用なナフチリジン誘導体
TWI811703B (zh) 2020-06-19 2023-08-11 瑞士商赫孚孟拉羅股份公司 與ｃｄ３及ｃｄ１９結合之抗體
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2021260675A1 (en) 2020-06-24 2021-12-30 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
WO2022003554A1 (en) 2020-07-01 2022-01-06 Pfizer Inc. Biomarkers for pd-1 axis binding antagonist therapy
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
KR20230087451A (ko) 2020-09-02 2023-06-16 주식회사 파멥신 암 환자를 치료하기 위한 pd-1 길항제 및 vegfr-2에 대한 길항제의 조합 요법
IL301701A (en) 2020-12-18 2023-05-01 Lamkap Bio Beta Ag Bispecific antibodies against CEACAM5 and CD47
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022162518A2 (en) 2021-01-28 2022-08-04 Janssen Biotech, Inc. Psma binding proteins and uses thereof
JP2024505562A (ja) 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法
EP4301733A1 (en) 2021-03-02 2024-01-10 GlaxoSmithKline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
US20240166747A1 (en) 2021-03-31 2024-05-23 Glazosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022217123A2 (en) 2021-04-08 2022-10-13 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
CA3213917A1 (en) 2021-04-09 2022-10-13 Nicolas Poirier New scaffold for bifunctional molecules with improved properties
WO2022227015A1 (en) 2021-04-30 2022-11-03 Merck Sharp & Dohme Corp. Il4i1 inhibitors and methods of use
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
CA3218590A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against CD40 and CD137 in combined cancer therapy
AU2022317124A1 (en) * 2021-07-28 2024-03-14 Anwita Biosciences, Inc. Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications
WO2023010080A1 (en) 2021-07-30 2023-02-02 Seagen Inc. Treatment for cancer
WO2023039583A1 (en) * 2021-09-10 2023-03-16 Trustees Of Tufts College Anti-pd-1 immunoglobulin polypeptides and uses thereof
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023166418A2 (en) 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof
WO2023172643A1 (en) * 2022-03-08 2023-09-14 Whitehead Institute For Biomedical Research The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023230541A1 (en) 2022-05-27 2023-11-30 Viiv Healthcare Company Piperazine derivatives useful in hiv therapy
WO2023242351A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
WO2024115725A1 (en) 2022-12-01 2024-06-06 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2110444T3 (es) 1990-06-11 1998-02-16 Nexstar Pharmaceuticals Inc Ligandos de acidos nucleicos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
EP0558671B1 (en) 1990-11-21 1999-01-27 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DK0942968T3 (da) 1996-12-03 2008-06-23 Amgen Fremont Inc Fuldt humane antistoffer, der binder EGFR
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
US20020054869A1 (en) 2000-09-01 2002-05-09 Han-Mo Koo Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
EP2275102B1 (en) 2002-03-13 2015-07-29 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1556684A4 (en) 2002-11-01 2008-01-23 Univ Colorado Regents QUANTITATIVE ANALYSIS OF PROTEIN ISOFORMS USING FLIGHT TIME MASS SPECTROMETRY BY MATRIX ASSISTED LASER DESORPTION / IONIZATION
AU2003274576A1 (en) 2002-11-15 2004-06-15 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
PT2298768E (pt) 2004-06-11 2012-12-05 Japan Tobacco Inc Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
MX2007004781A (es) * 2004-10-20 2007-05-11 Applied Research Systems Derivados de 3-arilamino piridina.
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
PT2161336E (pt) 2005-05-09 2013-10-03 Ono Pharmaceutical Co Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿
HUE027370T2 (en) 2005-06-22 2016-10-28 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CN104892582B (zh) 2005-10-07 2019-09-27 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
CA2660546A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008101840A1 (en) 2007-02-23 2008-08-28 F. Hoffmann-La Roche Ag Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells
US7919033B2 (en) * 2007-07-18 2011-04-05 Ngk Insulators, Ltd. Method of manufacturing honeycomb structure and manufacturing apparatus thereof
ES2383927T3 (es) 2007-08-16 2012-06-27 F. Hoffmann-La Roche Ag Hidantoínas sustituidas
EP2227469B9 (en) 2007-11-12 2014-09-10 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2009073533A2 (en) 2007-11-30 2009-06-11 Medarex, Inc. Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
PL2222675T3 (pl) 2007-12-19 2014-02-28 Genentech Inc 5-anilinoimidazopirydyny i sposoby zastosowania
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
EP2265609B1 (en) 2008-02-29 2012-09-05 Array Biopharma, Inc. Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors
US20110003859A1 (en) 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
PE20091623A1 (es) 2008-02-29 2009-11-19 Array Biopharma Inc DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA
EP2265608A2 (en) 2008-02-29 2010-12-29 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
MX2011000440A (es) 2008-07-11 2011-02-24 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
AU2009288289B2 (en) 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
WO2010056735A1 (en) 2008-11-11 2010-05-20 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity
EP3929216A1 (en) * 2008-12-09 2021-12-29 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PE20121816A1 (es) * 2009-10-12 2013-01-02 Hoffmann La Roche Combinaciones de un inhibidor de pi3k y un inhibidor de mek
EP2501237A1 (en) 2009-11-06 2012-09-26 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor
CN102713606A (zh) 2009-11-13 2012-10-03 无限制药股份有限公司 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
NO2504364T3 (es) 2009-11-24 2018-01-06
BR112012022210B1 (pt) 2010-03-04 2021-08-17 Macrogenics, Inc Anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
EP2580255B1 (en) 2010-06-11 2016-09-07 The Government of the United States of America as represented by the Secretary of the Navy Polyarylacetylenes containing siloxane, silane, and carborane moieties
PE20190262A1 (es) 2011-08-01 2019-02-25 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
SG11201401815XA (en) 2011-10-28 2014-05-29 Genentech Inc Therapeutic combinations and methods of treating melanoma
CN105189552B (zh) 2013-03-14 2019-08-02 基因泰克公司 抗b7-h4抗体和免疫缀合物
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
JP2016520643A (ja) 2013-06-03 2016-07-14 ノバルティス アーゲー 抗ｐｄ−ｌ１抗体とｍｅｋ阻害薬および／またはｂｒａｆ阻害薬の組み合わせ物
SG10202007111TA (en) 2014-07-15 2020-09-29 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors

Also Published As

Publication number Publication date
TW202216199A (zh) 2022-05-01
ZA201400612B (en) 2016-06-29
PH12018500365A1 (en) 2019-03-25
BR112014002353B1 (pt) 2022-09-27
KR102049817B1 (ko) 2019-12-02
AU2016201086B2 (en) 2017-11-02
JP2018008963A (ja) 2018-01-18
MX2019011424A (es) 2019-11-01
CO6900118A2 (es) 2014-03-20
PL2739358T3 (pl) 2019-04-30
MX2014001319A (es) 2014-02-27
AU2018200559B2 (en) 2019-05-09
AR087405A1 (es) 2014-03-19
WO2013019906A1 (en) 2013-02-07
EP2739358B1 (en) 2018-11-28
AU2016201086A1 (en) 2016-03-10
UA117220C2 (uk) 2018-07-10
CA2843595A1 (en) 2013-02-07
US20180021431A1 (en) 2018-01-25
IL230647B (en) 2020-05-31
JP2019196357A (ja) 2019-11-14
TR201820873T4 (tr) 2019-01-21
EP2739358A1 (en) 2014-06-11
JP2014525918A (ja) 2014-10-02
WO2013019906A9 (en) 2014-03-20
TW201318638A (zh) 2013-05-16
BR112014002353A2 (pt) 2017-02-21
CN103842030B (zh) 2018-07-31
TW202114735A (zh) 2021-04-16
SG10201606284UA (en) 2016-09-29
US20140341902A1 (en) 2014-11-20
JP6762274B2 (ja) 2020-09-30
IL274059A (en) 2020-06-30
AU2012290121B2 (en) 2015-11-26
EA201490369A1 (ru) 2014-08-29
MY193562A (en) 2022-10-19
TW201840336A (zh) 2018-11-16
IL230647A0 (en) 2014-03-31
CN103842030A (zh) 2014-06-04
IL274059B (en) 2021-10-31
BR112014002353A8 (pt) 2021-09-28
ES2708669T3 (es) 2019-04-10
NZ620411A (en) 2016-07-29
US10646567B2 (en) 2020-05-12
AU2019206076A1 (en) 2019-08-08
PH12018500365B1 (en) 2019-03-25
AU2018200559A1 (en) 2018-02-15
MA35366B1 (fr) 2014-08-01
EA026924B1 (ru) 2017-05-31
TWI835048B (zh) 2024-03-11
KR20190133790A (ko) 2019-12-03
CA2843595C (en) 2022-10-18
MX368257B (es) 2019-09-26
JP6238459B2 (ja) 2017-11-29
ECSP14013223A (es) 2014-03-31
TWI654994B (zh) 2019-04-01
MY170117A (en) 2019-07-05
CR20140034A (es) 2014-07-23
AU2012290121A1 (en) 2013-05-09
PE20141693A1 (es) 2014-11-24
BR122022000334B1 (pt) 2023-03-21
KR20140063643A (ko) 2014-05-27
PE20190262A1 (es) 2019-02-25
US9724413B2 (en) 2017-08-08

Similar Documents

Publication Publication Date Title
AR122743A2 (es) Composición farmacéutica de antagonistas de unión al eje pd-1 e inhibidores de mek
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
CL2013001093A1 (es) Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
UY33498A (es) Combinaciones de inhibidores de quinasas para el tratamiento de cancer
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
EA201270730A1 (ru) ИНГИБИТОРЫ КИНАЗЫ Cdc7 И ИХ ПРИМЕНЕНИЕ
UY36207A (es) Inhibidores de la syk
BR112016028642A2 (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
BR112014017985A8 (pt) Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
EA201692470A1 (ru) Фармацевтические комбинации
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου